1. Home
  2. YJ vs GRDX Comparison

YJ vs GRDX Comparison

Compare YJ & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunji Inc. American Depository Shares

YJ

Yunji Inc. American Depository Shares

HOLD

Current Price

$1.50

Market Cap

9.1M

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$2.16

Market Cap

7.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YJ
GRDX
Founded
2015
N/A
Country
China
United Kingdom
Employees
N/A
2
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
7.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
YJ
GRDX
Price
$1.50
$2.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.7K
77.1K
Earning Date
03-20-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$1.87
52 Week High
$2.67
$5.30

Technical Indicators

Market Signals
Indicator
YJ
GRDX
Relative Strength Index (RSI) 43.33 46.37
Support Level $1.38 $1.99
Resistance Level $1.72 $2.56
Average True Range (ATR) 0.13 0.22
MACD -0.05 0.05
Stochastic Oscillator 4.55 39.47

Price Performance

Historical Comparison
YJ
GRDX

About YJ Yunji Inc. American Depository Shares

Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: